GEOLOG Acquires Quad Ltd and QO Inc. to Enhance Global Wellsite Geology and Pore Pressure Services
GEOLOG International B.V. (“GEOLOG” or the “Company”), a leading independent provider of wellsite geosciences, drilling solutions and surface logging services to the energy industry, today announced the successful acquisition of Quad Ltd and QO Inc. (together, “Quad”). Quad is a long-standing provider of wellsite and operations geologists, along with advanced pore pressure and fracture gradient analysis services.
This strategic bolt-on acquisition significantly enhances GEOLOG’s portfolio of advanced subsurface and drilling support services and solidifies its operational presence globally.
GEOLOG and Quad have a history of successful collaboration on numerous international projects, serving a broad spectrum of energy clients. Integrating Quad’s highly experienced personnel and specialized technical capabilities will strengthen GEOLOG’s capacity to support clients in complex drilling environments, spanning from exploration through development and production phases.
“Quad has been a trusted partner for a long time, and we are delighted to formally welcome their team into the GEOLOG family,” commented Richard Calleri, Chief Executive Officer of GEOLOG. “Their industry reputation for excellence in wellsite and operations geology, as well as pore pressure and fracture gradient analysis, is exceptional. By combining Quad’s specialist knowledge with GEOLOG’s extensive global footprint and technology platform, we can now offer a truly integrated suite of solutions, which is critical for technically challenging and high-risk wells.”
Quad is active across the globe, providing clients with seasoned geological professionals and recognized expertise in critical disciplines like pore pressure prediction and fracture gradient analysis. Their extensive experience includes supporting High-Pressure, High-Temperature (HPHT) wells, deepwater operations, and unconventional plays, delivering insights vital for optimizing well planning, managing drilling risks, and enhancing overall safety and performance.
By incorporating Quad’s services into the existing GEOLOG portfolio, clients will gain:
- Expanded Talent Pool: Access to a larger global team of wellsite and operations geologists with deep experience across diverse geological and operating environments.
- Strengthened Risk Management: Superior pore pressure and fracture gradient analysis capabilities to support well design, real-time drilling decisions, and effective risk mitigation.
- Comprehensive Service Delivery: A broader, integrated solution that combines GEOLOG’s advanced surface logging and digital workflows with Quad’s specialist consulting and onsite geological expertise.
Over the coming months, GEOLOG and Quad will coordinate service delivery, align technical workflows, and further integrate their offerings.
Shaun Coogan, Director of Quad, added, “This is a logical next step in our long-standing relationship with GEOLOG. We share a commitment to technical excellence and a client-focused culture. Together, we are better equipped to help our clients reduce risk, improve well performance, and deliver their projects safely and efficiently worldwide.”
The terms of the transaction were not disclosed.
About GEOLOG
GEOLOG is a leading independent global provider of wellsite geosciences, surface logging, and advanced drilling support services to the energy industry. Operating in over 40 countries, GEOLOG delivers high-quality formation evaluation, drilling optimization, reservoir characterization and real-time data services that help clients reduce risk, improve well performance and lower overall field development costs. For more information, please visit: www.geolog.com
About Quad Ltd and QO Inc.
Quad Ltd and QO Inc. are specialized providers of wellsite and operations geology, pore pressure and fracture gradient analysis services to the international oil and gas industry. Operating in all major oil and gas basins worldwide, Quad supports operators and service companies from exploration through development, with a strong focus on complex wells, HPHT environments and technically challenging projects.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20260106566121/en/
Contacts
Richard Calleri, CEO
GEOLOG International B.V.
media@geolog.com
www.geolog.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.geolog.com&
esheet=54387529&newsitemid=20260106566121&lan=en-US&anchor=www.geolog.com&index=
3&md5=1c13ab1e67a50437cc8576524746359e
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom